Objective Our study aims to assay the irisin level and investigate the relationships of irisin level with body mass index (BMI), body composition and bone metabolism in the polycystic ovary syndrome (PCOS) and control women.
Introduction
Irisin, which was recently identified as a myokine and an adipokine, transforms white adipose tissue to brown adipose tissue and has increasingly caught the attention of the researchers [1] . Hence, some scientists speculate the potential role of irisin in preventing from type 2 diabetes and metabolic diseases associated with obesity [such as polycystic ovary syndrome (PCOS)]. The expression of irisin was reported to decrease in type 2 diabetes and non-alcoholic fatty liver disease [2] [3] [4] [5] and increase in patients with metabolic disorder [6] and prior gestational diabetes mellitus [7] . To date, there have been reports of the positive [2, 6, 8, 9] , negative [4, [10] [11] [12] and no correlations [3, 13, 14] between irisin and body mass index (BMI). It was also found that irisin could enhance osteoblast differentiation in vitro [15] and circulating irisin levels were associated with osteoporotic fracture(s) in postmenopausal women [16, 17] . Recently, it has been shown in rodents that irisin displays anabolic actions on the skeleton and improves cortical bone mass and strength. Irisin can modulate the skeletal genes (Opn and Sost genes) expression in whole tibia and stimulate osteogenesis in vivo [18] .
The PCOS is a very common reproductive endocrinological disorder [19] , which is often associated with infertility, dysfunctional uterine bleeding and hyperandrogenism. It was reported a rate of abnormal glucose tolerance of 23.08% in PCOS patients [20] . PCOS subjects also appear to have a high risk of suffering lipid metabolism disorder [21] , non-alcoholic fatty liver disease [22] and bone metabolic disorder [23] . The role of irisin in the development of PCOS is still ambiguous although this disease is associated with insulin resistance and increased BMI or T2DM. Chang et al. consider that irisin might contribute to the development of PCOS and may also represent novel PCOS biomarkers [24] . Li et al. reported that elevated circulating levels of irisin and the effect of metformin treatment in women with PCOS [25] . Katarzyna et al. found that plasma irisin concentrations in PCOS and healthy subjects are related to body adipose content [26] .
In this study, we aim to compare the serum irisin level between the PCOS and control women and investigate whether there are relationships of irisin level with BMI, body fat distribution and bone metabolism in these human bodies.
Methods

Study population
A total of 52 women with PCOS were recruited from the outpatient of the endocrinology department of Second Hospital of Jilin University from October 2012 to September 2014. All women were diagnosed as PCOS according to 2003 Rotterdam diagnostic criteria. Thirty nine women with regular menstrual period were enrolled as the control group. All 91 subjects were without thyroid disease or diabetes and denied smoking and alcohol habits. All subjects did not take medications such as oral contraceptives, metformin or corticosteroids that could interfere with glucose and bone metabolisms during the recent 1 year. The two groups were divided into four sub-groups according to BMI [normal weight subjects (BMI < 24) and overweight and obese subjects (BMI ≥ 24)] for further analysis. Nineteen new onset type 2 diabetes female patients were also recruited in our study. All participants were recorded of clinical and biochemical characteristics (age, BMI, waist and hip circumferences and menstruation situation).
Informed consent was signed before blood samples were collected. Intravenous fasting blood samples were collected from each participant and centrifuged to obtain serum. All serum samples were stored at À80°C for further use.
Assays
Serum luteinizing hormone (LH), follicle stimulating hormone (FSH), LH/FSH, prolactin, progesterone, oestrogen, total testosterone, fasting insulin (FIN) and C-peptide were tested by using automatic chemiluminescence immunoassay analyzer (Siemens ADVIA Centaur XP, Tarrytown, USA). Fasting blood glucose, total cholesterol, highdensity-lipoprotein cholesterol, low-density-lipoprotein cholesterol and triglyceride were tested using fully automatic biochemical analyzer (Beckman DxC800, USA). Serum irisin [EK-067-29, Phoenix Pharmaceuticals, USA; intra-assay coefficient of variation (CV) 6.80%, inter-assay CV 9.54%] and adiponectin (Elabscience, China; intra-assay CV 7.74%, inter-assay CV 10.02%) were determined with enzyme-linked immunosorbent assay (ELISA) according to manufacturers' instructions. Serum cross-linked C-telopeptide of type 1 collagen (CTx) and total procollagen type 1 N amino-terminal propeptide (P1NP) were measured by electrochemical luminescence method (Siemens ADVIA Centaur XP, Ireland). Bone mineral density (BMD) and body fat distribution were measured by dual energy X-ray absorptiometry (Hologic, USA).
Statistical analysis
Continuous variables for normal distribution were tested with the Kolmogorov-Smirnov test. Data that conformed to a normal distribution were expressed as mean ± stanndard deviation and analysed using independent samples t-test. Data that did not conform to normal distribution were expressed as M [P25; P75] and analyzed using Mann-Whitney test. Analysis of covariance was used to study the differences of irisin level between each group adjusted by age and BMI. Pearson's correlation coefficient (r) is used to calculate the correlation between irisin level and parametric continuous variables, and Spearman's correlation coefficient (rho) to calculate the nonparametric variables. The association between irisin and the other variables was calculated by using partial correlation coefficients (r p ). Two-tailed p-values < 0.05 were considered statistically significant. Statistical analyses were performed with SPSS version 19.0 Software.
Results
Measurements of anthropometric and metabolic characteristics showed that BMI, weight, waist, waist-hip ratio and levels of LH, total testosterone, LH/FSH, triglyceride, total cholesterol and low-density-lipoprotein cholesterol of PCOS patients were significantly higher than those of control women. Similarly, PCOS patients exhibited significantly higher homeostatic model assessment of insulin resistance (HOMA-IR) and levels of fasting blood glucose and FIN compared with those of control women. The level of estradiol of PCOS patients was significantly lower than that of control women as expected (Table 1) .
Serum irisin level of PCOS did not show a significant difference compared with control subjects although it was decreased ( and overweight and obesity PCOS group (n = 37, BMI = 29.08 ± 4.23). The one-way analysis of variance indicated that there were no significant differences in above four groups. Analysis of covariance revealed that BMI and age had no correlation with irisin level. In addition, BMI and age matched T2DM female patients (n = 19, BMI = 22.48 ± 3.60, age = 23.26 ± 7.59 years) had significantly reduced levels of irisin and adiponectin as compared with control and PCOS women. Levels of adiponectin in PCOS patients were significantly decreased compared with control women (Figure 1) .
In this study, no differences were found in BMD between control and PCOS women (p > 0.05). However, PCOS women showed significantly higher levels of head fat%, android fat%/gynoid fat% (A/G), fat mass/height 2 , %fat trunk/%fat legs, total lean mass, trunk lean mass, subtotal lean mass, lean mass/height 2 , and appendicular lean mass/height 2 , and lower levels of trunk/limb fat mass ratio than controls in body composition ( Table 2) .
The positive associations of irisin with BMD, right arm BMD, right ribs bone mineral content and BMD in controls were found, while there was no association of those in PCOS women (Table 3) . Interestingly, we did not find the association of irisin with bone turnover markers (including P1NP and CTx) in control (Table 3) . Spearman correlations analysis revealed that irisin concentrations were significantly correlated with prolactin (rho = 0.321, p = 0.049) in control women. No correlation was observed between irisin and BMI (r = 0.217, p = 0.185; r = 0.174, p =0.218) and age (r = 0.181, p = 0.269; r =0.124, p = 0.383) either in control or PCOS groups. Partial correlations analysis indicated a positive correlation between serum irisin levels and BMD in the control group and a negative correlation in the PCOS group, after BMI and age adjusted (Table 4) . Furthermore, regression estimated equation was received by the analysis of regression, which was that Y = 282.379 + 0.005 X (Y = irisin concentrations; X = total lean mass; p = 0.021) in the PCOS group. That indicated total lean mass has a significant effect on irisin concentration in the PCOS group. But, there is no statistical significance in the regression-estimated equation between total lean mass and irisin concentrations in the control group.
Discussion
Polycystic ovary syndrome subjects display significantly higher total cholesterol, FIN and HOMA-IR and lower high-density-lipoprotein cholesterol and adiponectin levels compared with the control group in our study. Measurements of HOMA-IR indicate that glucose and insulin metabolisms in PCOS patients are significantly less efficient than those of control women. The adipocyte-derived hormone adiponectin concentrations are positively correlated with insulin sensitivity [27] . These data show that the glucose and lipid metabolisms are remarkably different in control and PCOS women and there is a close correlation with glycolipid metabolism.
Recently, it has been developed as a quantitative mass spectrometry assay for the detection of human irisin in plasma because many human irisin antibodies used in commercial ELISA kits lack required specificity [28] , which shows that human irisin circulates at~3.6 ng/mL in sedentary individuals and significantly increased tõ 4.3 ng/mL after aerobic physical activity [29] . This reports demonstrated the existence of irisin in circulation although these circulating levels of irisin are much lower than those found in our article (~500 ng/mL) by ELISA. ELISA kit used may also recognize other molecules similar to irisin such as fibronectin-like domains. But irisin antibody used in our ELISA assay can capture the full-length glycosylated irisin and reported to have a detection range of 0.1-1000 ng/mL and a minimal cross-reactivity (~9%) with fibronectin type III domain-containing protein 5 (FNDC5) according to manufacturers' instructions. Most of the studies demonstrated an irisin level at hundreds of nanogram per millilitre when using this ELISA kit [6, 17] , and this stable concentration of irisin can be used to show a validation correlation with some body parameters. Certainly, it will be optimal if we can calibrate human irisin level by using mass spectrometry or improving the specificity of irisin antibody.
In our study, PCOS patients have abnormal fat and lean mass distributions compared with controls including lower trunk/limb fat mass ratio, higher A/G ratio and total lean mass, which is consistent with the findings of Kogure et al. [30] . It is well known skeletal muscle, liver, heart and brain tissue express high levels of irisin, other tissues like adipose tissue also expressed and secreted a low fraction of irisin [31] . From our results, we verified that the total lean mass was significantly related with irisin concentration in the PCOS group. The increased lean mass that may be promoted by a higher level of androgen in PCOS patients [32] could contribute to the secretion of circulating irisin. On the other hand, there are certain studies shown serum irisin levels decreased in central obese subjects [33] . As a better predictor of visceral fat than BMI or waist-hip ratio, A/G ratio [34] measured by dual energy X-ray absorptiometry has been found increased in PCOS women. Some studies have reported that visceral fat is mainly constituted from white adipose tissue but not brown adipose mass [35] . Lower trunk/limb fat mass in these women may also reduce Figure 1 . Serum levels of irisin (A) and adiponectin (B) in polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) patients. The value in parentheses is the number of samples. P-values are assessed by independent samples t-test. *p < 0.05; **p < 0.01 [36] . Of note, stimulation of browning on adipocytes may enhance irisin production [12] , and then the abnormal brown fat distribution in PCOS patient accounts for the decreasing secretion of irisin. The discrepancy role of lean mass and fat mass in irisin secretion in PCOS patients may be the reason that the irisin level did not show the significant difference from the controls. It is also very interesting to find that type 2 diabetics show a significantly decreased irisin level compared with control and PCOS subjects when exclude androgen-driven lean mass factor. Type 2 diabetes is linked to more visceral fat, less thigh subcutaneous fat and more fat infiltration in muscle compared with persons without diabetes [37] [38] [39] . Certainly, we should do more exploring on these primary results.
No correlations between irisin and BMI and age were found in this study, which is consistent with the findings of Gouni et al. [13, 14] . Instead, our results demonstrated that there was a positive correlation between serum irisin levels and BMD in the control group and a negative relationship in PCOS patients after age and BMI adjusted. One study reported that circulating irisin is associated with osteoporotic fractures in postmenopausal women [16] . Singhal et al. also observed positive association of irisin levels with bone density and strength estimates in athletes [40] . Irisin can enhance osteoblast differentiation in vitro [15] and increase bone trabecular volume and cortical thickness in mice in vivo [41] . So irisin may be a muscle-derived bone anabolic factor and a useful biomarker for bone metabolism. But in PCOS women, some reports have shown bone metabolic disturbances because of different extent of excess endogenous androgen and hyperinsulinemia [23, 42] . The negative correlation between irisin and BMD in PCOS may be caused by this anomalous bone metabolism. Interestingly, we did not find the correlation between irisin and the biomarkers of bone turnover (P1NP and CTx). Relationships of irisin and other bone metabolic markers remain to be fully clarified. The association of the exercise-stimulated hormone irisin with BMD in the right arm may be explained by that subjects enrolled in this study are right-hand dominance; so muscle-derived irisin level is consistent with the higher frequency movement of the right arm. In our study, the level of adiponectin is significantly reduced in PCOS and T2D women compared with controls and which show the adipocyte factor is related to the disease process. Adiponectin is secreted primarily in white adipose tissue and also in brown adipose tissue, which concentrations are lower in subjects with obesity, metabolic syndrome and cardiovascular disease [43, 44] . But there are no correlations found between adiponection and body composition and bone metabolism, which is very different from irisin. The result may be explained by that irisin is not only a myokine but also an adipocytokine, while adiponectin is synthesized primarily in adipose tissue.
Conclusion
In conclusion, circulating irisin in PCOS is related to lean mass and BMD. This suggests that the exercise-stimulated hormone irisin, as a myokine and adipocytokine, is also associated with bone metabolism, which shows the crosstalk between different organs in human body and irisin takes a role in the development of PCOS.
